… increases the clinical effectiveness of each separately, we recommend the clinical use of …
of bone metastases and progression of prostate cancer. Further studies are needed of bone …

… by androgen blockade in clinical stage B2 prostate cancer. The Lupron depot neoadjuvant
prostate cancer study group. J Urol 1995; 154: 424-8 33. Vaillancourt L, Ttu B, Fradet Y, et al. …

… or hydrocortisone) has shown clinical efficacy as palliative treatment for a proportion of
patients (about 35 to 40%) with hormone-resistant advanced prostate cancer, a disease which …

… resistant prostate cancer (mCRPC). This study was designed to evaluate the clinical efficacy
… bicalutamide in an earlier setting of metastatic hormone-sensitive prostate cancer (mHSPC). …

… prostate cancer in Japan, is still lower than those in Western countries. However, prostate
cancer … mortality rate, 40% of all registered Japanese prostate cancer cases (n = 4529) in 2000 …

… was observed in aggressive prostate cancers [20, 21]. … The inhibition of mTOR pathway
have shown clinical efficacy … clinical studies exploring its inhibition with modest efficacy in …

… treatment of prostate cancer for >3 months and hormone refractory prostate cancer. … The
secondary end points were clinical assessment of prostate cancer and clinical responses based …

… This discrepancy in the clinical evaluation of PDI … prostate cancer in different ethnic or
national populations. In this report, we present the results of using PDI to detect prostate cancer in …

… to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). …
Metastatic castration-resistant prostate cancer patients derived clinical benefits with …

… resistant prostate cancer. This review provides, firstly a concise overview of the clinical
development, use and effectiveness of enzalutamide in the treatment of advanced prostate cancer…